Effect of co-administration of granulocyte colony-stimulating factor on interferon therapy.
The effect of co-administration of granulocyte colony-stimulating factor (G-CSF), as an antineutropenia agent, on interferon therapy was examined in a mouse model, in anticipation of an enhancement of interferon efficacy, because neutrophils induced by G-CSF are thought to act as antitumor effectors. G-CSF was intraperitoneally co-administered with human interferon alpha A/D (IFN) on Day 6 to Day 10 after intradermal inoculation of Meth A fibrosarcoma. Although the co-administration of G-CSF could protect against neutropenia and leukopenia induced by IFN, it did not enhance the regression of tumor, and rather reduced the prolongation of survival time and the long-term survival incidence of IFN therapy. The subsequent in vitro study showed that the antiproliferative activity of peripheral blood leukocytes from Meth A-bearing mice given both IFN and G-CSF was much weaker than that of mice given IFN alone. Whether the observed nullifying effect of G-CSF on IFN therapy is also the case with tumors other than Meth A is open to further study.
Segawa
K
K
Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research, Tokyo.
Suhara
Y
Y
Ueno
Y
Y
Kataoka
T
T
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005354:Fibrosarcoma / Q000473:pathology / Q000628:therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000627:therapeutic use*; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000473:pathology / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor